Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Humira, adalimumab, Date of authorisation: 08/09/2003, Revision: 98, Status: Authorised

Human medicines European public assessment report (EPAR): Leqembi, lecanemab, Date of authorisation: 15/04/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Arikayce liposomal, amikacin, Date of authorisation: 27/10/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Signifor, pasireotide, Date of authorisation: 24/04/2012, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Iqirvo, elafibranor, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Loqtorzi, toripalimab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised